Advertisement

Positron Emission Tomography and Computed Tomography Measurement of Brown Fat Thermal Activation: Key Tool for Developing Novel Pharmacotherapeutics for Obesity and Diabetes

  • Monte S. BuchsbaumEmail author
  • Alex DeCastro
Chapter

Abstract

We obtained 18F-deoxyglucose (FDG) positron emission tomography scans and CT scans of the upper thorax in nine insulin-resistant adults and two overweight healthy volunteers to assess quantitative glucose metabolic rate of brown and white fat. Scans were obtained following 90 min of exposure to cold (67–68 °F) and warm(72–73°) air temperature. FDG scans were converted to micromoles glucose/100 g/min using PMOD Technologies, Zurich, Switzerland, and the arterial input function from the aorta image. The initial high-resolution 200MA CT was used to coregister both PET and CT images. CT masks of 7 Hounsfield unit bands, −600 to −160 (mainly lung), −160 to −120, −120 to −80, −80 to −40, −40 to 0, 0 to 100 (muscle), and 100 to 600 (bone and some muscle), were computed. Cold minus warm metabolic rate images were obtained, and the greatest cold minus warm effect was found in the fat range with Hounsfield levels from −160 to −60 units, consistent with earlier studies of brown fat. This was confirmed with three-way ANOVA with repeated measures (cold/warm × Hounsfield unit band × thorax level). This algorithmic method avoids bias associated with visual tracing of fat types. Leg muscle tissue FDG and CT were obtained on eight of the subjects and showed leg muscle metabolism higher during the warm than cold conditions. This study demonstrates that brown > white fat regions of the upper thorax demonstrate thermal sensitivity and that FDG-PET/CT can provide a potentially useful measure of the pharmacological effects of brown fat enhancing action of new treatments.

Keywords

Adipose tissue Fluorodeoxyglucose Computed tomography Temperature Thermogenesis Homeostasis Obesity Diabetes 

Notes

Acknowledgments

The authors thank Andrew Krentz, Linda Morrow, and Marcus Hompesch for their support and useful advice at varied stages of the preparation of this chapter. Gisela Peterson and Laurel Glockler provided careful data organization support. George Madirossian provided assistance with scanner calibration and phantoms, Tim Erickson with electronic records, and Steven Hardy with file organization and scanner operation. Didier Laurent made useful suggestions for the data analysis.

References

  1. 1.
    English E, Lenters-Westra E. HbA1c method performance: the great success story of global standardization. Crit Rev Clin Lab Sci. 2018;55:1–12.Google Scholar
  2. 2.
    Marzona I, et al. Are all people with diabetes and cardiovascular risk factors or microvascular complications at very high risk? Findings from the risk and prevention study. Acta Diabetol. 2017;54(2):123–31.PubMedGoogle Scholar
  3. 3.
    Xiang AS, et al. Brown adipose tissue and lipid metabolism: new strategies for identification of activators and biomarkers with clinical potential. Pharmacol Ther. 2018;192:141–9.PubMedGoogle Scholar
  4. 4.
    Steinberg GR. Cellular energy sensing and metabolism-implications for treating diabetes: the 2017 outstanding scientific achievement award lecture. Diabetes. 2018;67(2):169–79.PubMedGoogle Scholar
  5. 5.
    Wilson JP, et al. Ratio of trunk to leg volume as a new body shape metric for diabetes and mortality. PLoS One. 2013;8(7):e68716.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Kuk JL, et al. Does measurement site for visceral and abdominal subcutaneous adipose tissue alter associations with the metabolic syndrome? Diabetes Care. 2006;29(3):679–84.PubMedGoogle Scholar
  7. 7.
    Brown RE, Kuk JL, Lee S. Measurement site influences abdominal subcutaneous and visceral adipose tissue in obese adolescents before and after exercise. Pediatr Obes. 2015;10:98–104.PubMedGoogle Scholar
  8. 8.
    Schulz TJ, Tseng YH. Brown adipose tissue: development, metabolism and beyond. Biochem J. 2013;453(2):167–78.PubMedGoogle Scholar
  9. 9.
    Fenzl A, Kiefer FW. Brown adipose tissue and thermogenesis. Horm Mol Biol Clin Invest. 2014;19(1):25–37.Google Scholar
  10. 10.
    Arch JR. Thermogenesis and related metabolic targets in anti-diabetic therapy. Handb Exp Pharmacol. 2011;4(203):201–55.Google Scholar
  11. 11.
    Arch JR, Trayhurn P. Detection of thermogenesis in rodents in response to anti-obesity drugs and genetic modification. Front Physiol. 2013;4:64.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Clapham JC, Arch JR. Targeting thermogenesis and related pathways in anti-obesity drug discovery. Pharmacol Ther. 2011;131(3):295–308.PubMedGoogle Scholar
  13. 13.
    Peirce V, Vidal-Puig A. Regulation of glucose homoeostasis by brown adipose tissue. Lancet Diabetes Endocrinol. 2013;1(4):353–60.PubMedGoogle Scholar
  14. 14.
    Ouellet V, et al. Brown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humans. J Clin Invest. 2012;122(2):545–52.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Cypess AM, Kahn CR. The role and importance of brown adipose tissue in energy homeostasis. Curr Opin Pediatr. 2010;22(4):478–84.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Sims EA. Storage and expenditure of energy in obesity and their implications for management. Med Clin North Am. 1989;73(1):97–110.PubMedGoogle Scholar
  17. 17.
    Tupone D, Madden CJ, Morrison SF. Autonomic regulation of brown adipose tissue thermogenesis in health and disease: potential clinical applications for altering BAT thermogenesis. Front Neurosci. 2014;8:14.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Mirbolooki MR, et al. Quantitative assessment of brown adipose tissue metabolic activity and volume using 18F-FDG PET/CT and β3-adrenergic receptor activation. EJNMMI Res. 2011;1(1):30.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Mirbolooki MR, et al. Targeting presynaptic norepinephrine transporter in brown adipose tissue: a novel imaging approach and potential treatment for diabetes and obesity. Synapse. 2013;67(2):79–93.PubMedGoogle Scholar
  20. 20.
    Mirbolooki MR, et al. Adrenergic pathway activation enhances brown adipose tissue metabolism: a [(1)(8)F]FDG PET/CT study in mice. Nucl Med Biol. 2014;41(1):10–6.PubMedGoogle Scholar
  21. 21.
    Lidell ME, et al. Evidence for two types of brown adipose tissue in humans. Nat Med. 2013;19(5):631–4.PubMedGoogle Scholar
  22. 22.
    Lidell ME, Betz MJ, Enerback S. Two types of brown adipose tissue in humans. Adipocytes. 2014;3(1):63–6.Google Scholar
  23. 23.
    Orava J, et al. Different metabolic responses of human brown adipose tissue to activation by cold and insulin. Cell Metab. 2011;14(2):272–9.PubMedGoogle Scholar
  24. 24.
    Orava J, et al. Blunted metabolic responses to cold and insulin stimulation in brown adipose tissue of obese humans. Obesity (Silver Spring). 2013;21(11):2279–87.Google Scholar
  25. 25.
    Enerback S. Brown adipose tissue in humans. Int J Obes. 2010;34(Suppl 1):S43–6.Google Scholar
  26. 26.
    Johnstone EC, et al. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet. 1976;2(7992):924–6.PubMedGoogle Scholar
  27. 27.
    Raju TN. The Nobel chronicles. 1979: Allan MacLeod Cormack (b 1924); and Sir Godfrey Newbold Hounsfield (b 1919). Lancet. 1999;354(9190):1653.PubMedGoogle Scholar
  28. 28.
    Jernigan TL, Zatz LM, Naeser MA. Semiautomated methods for quantitating CSF volume on cranial computed tomography. Radiology. 1979;132(2):463–6.PubMedGoogle Scholar
  29. 29.
    Heymsfield SB, et al. Assessing skeletal muscle mass: historical overview and state of the art. J Cachexia Sarcopenia Muscle. 2014;5:9–18.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Bulcke JA, et al. Computed tomography of the human skeletal muscular system. Neuroradiology. 1979;17(3):127–36.PubMedGoogle Scholar
  31. 31.
    Haggmark T, Jansson E, Svane B. Cross-sectional area of the thigh muscle in man measured by computed tomography. Scand J Clin Lab Invest. 1978;38(4):355–60.PubMedGoogle Scholar
  32. 32.
    Buchsbaum R. Size of explant and volume of medium in tissue cultures. In: Zoology. Chicago: The University of Chicago; 1932.Google Scholar
  33. 33.
    Pasanisi F, et al. Evidence of brown fat activity in constitutional leanness. J Clin Endocrinol Metab. 2013;98(3):1214–8.PubMedGoogle Scholar
  34. 34.
    Saito M, et al. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes. 2009;58(7):1526–31.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Ouellet V, et al. Outdoor temperature, age, sex, body mass index, and diabetic status determine the prevalence, mass, and glucose-uptake activity of 18F-FDG-detected BAT in humans. J Clin Endocrinol Metab. 2011;96(1):192–9.PubMedGoogle Scholar
  36. 36.
    Borkan GA, et al. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr. 1982;36(1):172–7.PubMedGoogle Scholar
  37. 37.
    Grauer WO, et al. Quantification of body fat distribution in the abdomen using computed tomography. Am J Clin Nutr. 1984;39(4):631–7.PubMedGoogle Scholar
  38. 38.
    Cohade C, et al. Uptake in supraclavicular area fat (“USA-Fat”): description on 18F-FDG PET/CT. J Nucl Med. 2003;44(2):170–6.PubMedGoogle Scholar
  39. 39.
    Cypess AM, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360(15):1509–17.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Blondin DP, et al. Increased brown adipose tissue oxidative capacity in cold-acclimated humans. J Clin Endocrinol Metab. 2014;99:jc20133901.Google Scholar
  41. 41.
    van Marken Lichtenbelt WD, et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009;360(15):1500–8.PubMedGoogle Scholar
  42. 42.
    Baba S, et al. CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies. J Nucl Med. 2010;51(2):246–50.PubMedGoogle Scholar
  43. 43.
    Shao X, et al. Characterization of brown adipose tissue (1)(8)F-FDG uptake in PET/CT imaging and its influencing factors in the Chinese population. Nucl Med Biol. 2016;43(1):7–11.PubMedGoogle Scholar
  44. 44.
    Pace L, et al. Determinants of physiologic 18F-FDG uptake in brown adipose tissue in sequential PET/CT examinations. Mol Imaging Biol. 2011;13(5):1029–35.PubMedGoogle Scholar
  45. 45.
    Au-Yong IT, et al. Brown adipose tissue and seasonal variation in humans. Diabetes. 2009;58(11):2583–7.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Hu HH, et al. Differential computed tomographic attenuation of metabolically active and inactive adipose tissues: preliminary findings. J Comput Assist Tomogr. 2011;35(1):65–71.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Virtanen KA, et al. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009;360(15):1518–25.PubMedGoogle Scholar
  48. 48.
    Virtanen KA, et al. Human adipose tissue glucose uptake determined using [(18)F]-fluoro-deoxy-glucose ([(18)F]FDG) and PET in combination with microdialysis. Diabetologia. 2001;44(12):2171–9.PubMedGoogle Scholar
  49. 49.
    Yoneshiro T, et al. Age-related decrease in cold-activated brown adipose tissue and accumulation of body fat in healthy humans. Obesity (Silver Spring). 2011;19(9):1755–60.Google Scholar
  50. 50.
    Pfannenberg C, et al. Impact of age on the relationships of brown adipose tissue with sex and adiposity in humans. Diabetes. 2010;59(7):1789–93.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Dinas PC, et al. Association between habitual physical activity and brown adipose tissue activity in individuals undergoing PET-CT scan. Clin Endocrinol. 2015;82(1):147–54.Google Scholar
  52. 52.
    Sachpekidis C, et al. Dynamic (18)F-fluorodeoxyglucose positron emission tomography/CT in hibernoma: enhanced tracer uptake mimicking liposarcoma. World J Radiol. 2013;5(12):498–502.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Agrawal A, et al. Report of two cases of fluorodeoxyglucose positron emission tomography/computed tomography appearance of hibernoma: a rare benign tumor. Indian J Nucl Med. 2014;29(1):40–2.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Zingaretti MC, et al. The presence of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue. FASEB J. 2009;23(9):3113–20.PubMedGoogle Scholar
  55. 55.
    Yoneshiro T, et al. Impact of UCP1 and beta3AR gene polymorphisms on age-related changes in brown adipose tissue and adiposity in humans. Int J Obes. 2013;37(7):993–8.Google Scholar
  56. 56.
    Smith RE, Hock RJ. Brown fat: thermogenic effector of arousal in hibernators. Science. 1963;140(3563):199–200.PubMedGoogle Scholar
  57. 57.
    Muzik O, et al. 15O PET measurement of blood flow and oxygen consumption in cold-activated human brown fat. J Nucl Med. 2013;54(4):523–31.PubMedGoogle Scholar
  58. 58.
    Buchsbaum M, et al. Brown adipose tissue metabolic activity assessed with FDG-PET/CT correlates with BMI and glucose. Diabetologia. 2013;56:1–566.Google Scholar
  59. 59.
    Hui SCN, et al. Quantification of brown and white adipose tissue based on Gaussian mixture model using water-fat and T2* MRI in adolescents. J Magn Reson Imaging. 2017;46(3):758–68.PubMedGoogle Scholar
  60. 60.
    Franz D, et al. Discrimination between brown and white adipose tissue using a 2-point dixon water-fat separation method in simultaneous PET/MRI. J Nucl Med. 2015;56(11):1742–7.PubMedGoogle Scholar
  61. 61.
    Hui SCN, et al. Observed changes in brown, white, hepatic and pancreatic fat after bariatric surgery: evaluation with MRI. Eur Radiol. 2019;29:849–56.PubMedGoogle Scholar
  62. 62.
    Fuse S, et al. Brown adipose tissue density measured by near-infrared time-resolved spectroscopy in Japanese, across a wide age range. J Biomed Opt. 2018;23(6):1–9.PubMedGoogle Scholar
  63. 63.
    Ong FJ, et al. Recent advances in the detection of brown adipose tissue in adult humans: a review. Clin Sci (Lond). 2018;132(10):1039–54.Google Scholar
  64. 64.
    Law J, et al. Thermal imaging is a noninvasive alternative to PET/CT for measurement of brown adipose tissue activity in humans. J Nucl Med. 2018;59(3):516–22.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Sokoloff L, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28(5):897–916.PubMedGoogle Scholar
  66. 66.
    Eycleshymer AC, Schoemaker DM, Potter P, Smith C, Jones T. A cross-section anatomy. New York: D. Appleton and Company; 1911.Google Scholar
  67. 67.
    Gray H. Anatomy of the human body. Philadelphia: Lea and Febiger; 1959.Google Scholar
  68. 68.
    Orava J, et al. Brown adipose tissue function is accompanied by cerebral activation in lean but not in obese humans. J Cereb Blood Flow Metab. 2014;34:1018–23.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Jeremic N, Chaturvedi P, Tyagi SC. Browning of white fat: novel insight into factors, mechanisms, and therapeutics. J Cell Physiol. 2017;232(1):61–8.PubMedGoogle Scholar
  70. 70.
    Hanssen MJ, et al. Short-term cold acclimation improves insulin sensitivity in patients with type 2 diabetes mellitus. Nat Med. 2015;21(8):863–5.PubMedGoogle Scholar
  71. 71.
    Garito T, et al. Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals. Diabetes Obes Metab. 2018;20(1):94–102.PubMedGoogle Scholar
  72. 72.
    Sanchez-Infantes D, et al. Oncostatin m impairs brown adipose tissue thermogenic function and the browning of subcutaneous white adipose tissue. Obesity (Silver Spring). 2017;25(1):85–93.Google Scholar
  73. 73.
    Monti LD, et al. Decreased diabetes risk over 9 year after 18-month oral L-arginine treatment in middle-aged subjects with impaired glucose tolerance and metabolic syndrome (extension evaluation of L-arginine study). Eur J Nutr. 2018;57:2805–17.PubMedGoogle Scholar
  74. 74.
    Volkow ND, et al. Inverse association between BMI and prefrontal metabolic activity in healthy adults. Obesity (Silver Spring). 2009;17(1):60–5.Google Scholar
  75. 75.
    de Wit L, et al. Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res. 2010;178(2):230–5.PubMedGoogle Scholar
  76. 76.
    Sarwer DB, et al. Psychiatric diagnoses and psychiatric treatment among bariatric surgery candidates. Obes Surg. 2004;14(9):1148–56.PubMedGoogle Scholar
  77. 77.
    Rosenberger PH, Henderson KE, Grilo CM. Psychiatric disorder comorbidity and association with eating disorders in bariatric surgery patients: a cross-sectional study using structured interview-based diagnosis. J Clin Psychiatry. 2006;67(7):6.Google Scholar
  78. 78.
    Lier HO, et al. Prevalence of psychiatric disorders before and 1 year after bariatric surgery: the role of shame in maintenance of psychiatric disorders in patients undergoing bariatric surgery. Nord J Psychiatry. 2013;67:89–96.PubMedGoogle Scholar
  79. 79.
    Cunningham JL, et al. Investigation of antidepressant medication usage after bariatric surgery. Obes Surg. 2012;22(4):530–5.PubMedGoogle Scholar
  80. 80.
    Anderson JW, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002;10(7):633–41.PubMedGoogle Scholar
  81. 81.
    Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71(10):1259–72.PubMedGoogle Scholar
  82. 82.
    Tolstoy L. Anna Karenina. Gutenberg Project: Ebook; 1998.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.University of California, San DiegoLa JollaUSA
  2. 2.Department of PsychiatryUniversity of California, San DiegoLa JollaUSA

Personalised recommendations